← BIOMARIN PHARMACEUTICAL INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.1b |
$1.3b
+17.62%
|
$1.5b
+13.52%
|
$1.7b
+14.27%
|
$1.9b
+9.18%
|
$1.8b
-0.76%
|
$2.1b
+13.53%
|
$2.4b
+15.42%
|
$2.9b
+17.97%
|
$3.2b
+12.87%
|
$3.4b
+5.75%
|
|
| Cost of Goods and Services Sold | $209.6m |
$241.8m
+15.34%
|
$315.3m
+30.39%
|
$359.5m
+14.02%
|
$524.3m
+45.85%
|
$470.5m
-10.25%
|
$483.7m
+2.80%
|
$514.9m
+6.45%
|
$580.2m
+12.70%
|
$717.4m
+23.65%
|
$813.6m
+13.40%
|
|
| Gross Profit (Calculated) | $907.2m |
$1.1b
+18.15%
|
$1.2b
+9.71%
|
$1.3b
+14.34%
|
$1.3b
-0.62%
|
$1.4b
+2.96%
|
$1.6b
+17.20%
|
$1.9b
+18.11%
|
$2.3b
+19.39%
|
$2.5b
+10.12%
|
— | |
| Research and Development Expense | $661.9m | $610.8m | $696.3m | $715.0m | $628.1m | $628.8m | $649.6m | $746.8m | $747.2m | $921.9m | $987.6m | |
| Selling, General and Administrative Expense | $476.6m | $554.3m | $604.4m | $680.9m | $737.7m | $759.4m | $854.0m | $937.3m | $1.0b | $1.2b | $1.4b | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | — | $43.3m | $19.4m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | ($803.4m) |
($14.7m)
+98.17%
|
($123.5m)
-740.30%
|
($100.5m)
+18.67%
|
($36.8m)
+63.40%
|
($82.3m)
-123.97%
|
$149.6m
+281.64%
|
$158.1m
+5.71%
|
$484.2m
+206.28%
|
$409.5m
-15.43%
|
$149.3m
-63.53%
|
|
| Other Operating Income (Expense), Net | $4.9m | $8.0m | $2.2m | $6.9m | $7.1m | $11.8m | ($2.0m) | ($10.5m) | ($4.7m) | $9.0m | — | |
| Interest Expense, Debt | $29.8m | — | — | — | — | — | — | — | — | — | $83.6m | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | $0 | $714k | — | — | — | — | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | — | ($11.4m) | ($27.7m) | ($8.6m) | ($6.1m) | — | |
| Interest Expense (non-operating) | $39.5m | $42.7m | $43.7m | $23.5m | $29.3m | $15.3m | $16.0m | $17.3m | $12.7m | $10.9m | $83.6m | |
| Income (Loss) from Equity Method Investments | ($538k) | ($1.3m) | ($553k) | ($587k) | ($6k) | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $10.7m | ($19.5m) | ($128.7m) | ($182.1m) | ($162.9m) | ($259.3m) | ($299.4m) | ($453.8m) | $130.5m | ($262.6m) | $149.1m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($831.0m) | ($35.9m) | ($142.7m) | ($94.8m) | ($42.3m) | ($75.3m) | $149.6m | $188.6m | $541.8m | $482.5m | $149.1m | |
| Current Income Tax Expense (Benefit) | $27.2m | $36.7m | $2.9m | $11.8m | ($12.5m) | $4.3m | $60.1m | $65.9m | $58.8m | $84.8m | $76.1m | |
| Income Tax Expense (Benefit) | ($200.8m) | $81.2m | ($65.5m) | ($71.0m) | ($901.4m) | ($11.3m) | $8.0m | $20.9m | $114.9m | $133.6m | $76.1m | |
| Net Income (Loss) Attributable to Parent | ($630.2m) |
($117.0m)
+81.43%
|
($77.2m)
+34.03%
|
($23.8m)
+69.11%
|
$859.1m
+3702.40%
|
($64.1m)
-107.46%
|
$141.6m
+320.91%
|
$167.6m
+18.43%
|
$426.9m
+154.62%
|
$348.9m
-18.26%
|
$73.0m
-79.09%
|
|
| Earnings Per Share, Basic | ($3.80) | ($0.67) | ($0.44) | ($0.13) | $4.75 | ($0.35) | $0.76 | $0.89 | $2.25 | $1.82 | $0.37 | |
| Earnings Per Share, Diluted | ($3.81) | ($0.67) | ($0.44) | ($0.13) | $4.53 | ($0.35) | $0.75 | $0.87 | $2.21 | $1.80 | $0.37 | |
| Weighted Average Number of Shares Outstanding, Basic | 166.0m | 174.4m | 177.1m | 179.0m | 180.8m | 182.9m | 185.3m | 187.8m | 190.0m | 191.8m | 192.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | 166.2m | 174.4m | 177.3m | 179.0m | 191.7m | 182.9m | 189.0m | 191.6m | 196.7m | 197.4m | 196.1m | |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, Amortization | — | — | — | — | — | — | — | — | — | $7.4m | — | |
| Costs and Expenses | $1.9b | $1.3b | $1.6b | $1.8b | $1.9b | $1.9b | $1.9b | $2.3b | $2.4b | $2.8b | — | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | — | — | $12.6m | — | — | — | |
| Goodwill, Impairment Loss | — | — | — | — | $0 | $0 | — | — | — | — | — | |
| Reclassification from AOCI, Current Period, before Tax, Attributable to Parent | ($10.2m) | ($1.9m) | ($2.0m) | $15.9m | $13.7m | ($1.5m) | $36.6m | $164k | $14.9m | ($15.5m) | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.